- This event has passed.
Oncology Grand Rounds: Preserving CTLA4 Immune Tolerance Checkpoint for safer and more effective cancer immunotherapy
December 17, 2019 @ 4:00 pm - 5:00 pm
Yang Liu, PhD, Director, Division of Immunotherapy, Professor of Surgery, Institute of Human Virology, University of Maryland School of Medicine.
Liu’s contributions to the immunology field include pioneering work in the concept of T-cell co-stimulation and cancer immunity, the relationship between innate and adaptive immunity, and non-self-discrimination by the innate immune system. Many of the discoveries by Liu are being translated into immunotherapeutic approaches for cancer and autoimmune diseases, with a first-in-class immunotherapeutic now in a phase II clinical trial.
Recent papers:
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy, Trends in Pharmacological Sciences (2019), https://doi.org/10.1016/j.tips.2019.11.003 Trends in Pharmacological Science
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.
Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1. Epub 2019 Jul 2. PMID: 31267017
